Cerecor Inc., a Baltimore, MD-based clinical stage biopharmaceutical company developing treatments for patients suffering from nervous system disorders, closed the first tranche of a $32m Series B financing.
The round was led by New Enterprise Associates (NEA), Apple Tree Partners (ATP) and MPM Capital.
The company intends to use the funds for the development of its lead product candidate CERC-301.
Led by Blake M. Paterson, MD, co-founder and CEO, Cerecor is developing CERC-301, a selective antagonist of the NMDA receptor subunit 2B with the potential to be oral medication complimentary to existing treatments, in patients with depression and recent suicidal ideation who have not adequately responded to their current therapy.
FinSMEs
21/07/2014